SALIX PHARMACEUTICALS LTD 4

4 · SALIX PHARMACEUTICALS LTD · Filed Aug 26, 2014

Form 4

Period: 2014-08-22

Director

Transactions

Holdings

Common Stock
(indirect: By Trust)
10,450
Common Stock
(indirect: By Spouse)
6,500
Common Stock
(indirect: By Trust)
1,080
Common Stock
(indirect: By LP)
260
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (15,000 underlying)
15,000

Footnotes (4)

[F1]In connection with the transaction contemplated by the Agreement and Plan of Merger, dated as of July 8, 2014, by and among Salix Pharmaceuticals, Ltd. ("Salix"), Cosmo Pharmaceuticals S.p.A., Cosmo Technologies Limited and Sangiovese, LLC (the "Transaction"), the Board of Directors of Salix approved special grants (the "Special Grants") of restricted stock to directors and eligible employees, including Thomas W. D'Alonzo (the "Reporting Person"), intended to lessen the potential tax burden that would be triggered upon the completion of the Transaction. The reported transaction specified in this Form 4 consists solely of the shares of restricted stock granted to the Reporting Person pursuant to the Special Grants.
[F2]The shares are held by the Thomas W. D'Alonzo Rev Trust U/A DTD 10/24/2001 for which the Reporting Person serves as co-trustee.
[F3]The shares are held by the Rachel L. D'Alonzo Rev Trust U/A DTD 10/24/2001 for which the Reporting Person serves as co-trustee.
[F4]Options are 100% vested.

Documents

1 file